

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<u>In re</u> application of: BENOIT <i>et al.</i> Serial No. Filed: Simultaneously Herewith For: <i>Monoclonal Antibodies Against The Interferon Receptor, With Neutralizing Activity Against Type I Interferon</i>	Examiner: To be assigned Group Art Unit: To be assigned EXPRESS MAIL Express Mail Label No.: <u>EV 442861262 US</u> Date of Deposit: <u>APRIL 14, 2004</u> This paper and/or fee is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to Mail Stop PATENT APPLICATION/SEQUENCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
---	---

Mail Stop PATENT APPLICATION/SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**PRELIMINARY AMENDMENT re SEQUENCE LISTING AND
STATEMENT PURSUANT TO 37 C.F.R. § 1.821(f)**

Sir:

This amendment is submitted to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures in adherence with rules 37 C.F.R. §§ 1.821-1.825. Please amend the application as specified in **AMENDMENTS TO THE SPECIFICATION** beginning on page 2. Applicant's **REMARKS** begin on page 3.